CBio Receives Approvals for Rheumatoid Arthritis Trials

Australian-based drug development company CBio has announced a milestone achievement in its research in the treatment of rheumatoid arthritis.

Jason Yeates, MD, said that human research ethics committee approvals have been received for all Central and Eastern European clinical trial sites of XToll, the company’s potential drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis.

“These approvals are the first significant operational milestones which CBio plans to achieve over the next 12 months as we move towards completion of our 150 patient phase II clinical trial in rheumatoid arthritis,” said Yeates.

Regulatory approvals have also been received for sites in Bosnia and Georgia. Preparations for the commencement of recruitment in these countries are now concluding and a meeting of clinical investigators was held in Serbia in February.